Assessment of Erythroid and Granulocytic Hematopoietic Lineages in Patients with Non-Small-Cell Lung Carcinoma
- Autores: Goldberg V.1, Polyakova T.2,3, Popova N.1, Vysotskaya V.1, Simolina E.1, Belevich Y.1, Tuzikova T.1, Goldberg A.1, Zhdanov V.2, Miroshnichenko L.2, Udut E.2, Simanina E.2, Dygai A.2, Zyuz’kov G.2
-
Afiliações:
- Research Institute of Oncology, Tomsk National Research Medical Center
- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
- National Research Tomsk State University
- Edição: Volume 163, Nº 4 (2017)
- Páginas: 469-474
- Seção: Oncology
- URL: https://journals.rcsi.science/0007-4888/article/view/239000
- DOI: https://doi.org/10.1007/s10517-017-3830-y
- ID: 239000
Citar
Resumo
The toxic effects of combined cisplatin/docetaxel therapy cycles on erythroid and granulocytic hematopoietic lineages as well as their intercycle recovery were examined in patients with stage III-IV non-small-cell lung carcinoma. Responsiveness of the blood system to this therapy remained at a high level. Combined therapy pronouncedly activated the key elements of the erythroid and granulocytic hematopoietic lineages leading to accumulation of immature and mature myelokaryocytes in the bone marrow, enlargement of the medullary pool of mature neutrophils, and increase in the count of medullary erythroid and granulocytic precursor cells under conditions of their accelerated maturation.
Sobre autores
V. Goldberg
Research Institute of Oncology, Tomsk National Research Medical Center
Email: zgn@pharmso.ru
Rússia, Tomsk
T. Polyakova
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine; National Research Tomsk State University
Email: zgn@pharmso.ru
Rússia, Tomsk; Tomsk
N. Popova
Research Institute of Oncology, Tomsk National Research Medical Center
Email: zgn@pharmso.ru
Rússia, Tomsk
V. Vysotskaya
Research Institute of Oncology, Tomsk National Research Medical Center
Email: zgn@pharmso.ru
Rússia, Tomsk
E. Simolina
Research Institute of Oncology, Tomsk National Research Medical Center
Email: zgn@pharmso.ru
Rússia, Tomsk
Yu. Belevich
Research Institute of Oncology, Tomsk National Research Medical Center
Email: zgn@pharmso.ru
Rússia, Tomsk
T. Tuzikova
Research Institute of Oncology, Tomsk National Research Medical Center
Email: zgn@pharmso.ru
Rússia, Tomsk
A. Goldberg
Research Institute of Oncology, Tomsk National Research Medical Center
Email: zgn@pharmso.ru
Rússia, Tomsk
V. Zhdanov
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
Email: zgn@pharmso.ru
Rússia, Tomsk
L. Miroshnichenko
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
Email: zgn@pharmso.ru
Rússia, Tomsk
E. Udut
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
Email: zgn@pharmso.ru
Rússia, Tomsk
E. Simanina
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
Email: zgn@pharmso.ru
Rússia, Tomsk
A. Dygai
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
Email: zgn@pharmso.ru
Rússia, Tomsk
G. Zyuz’kov
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
Autor responsável pela correspondência
Email: zgn@pharmso.ru
Rússia, Tomsk
![](/img/style/loading.gif)